NHE9 induces chemoradiotherapy resistance in esophageal squamous cell carcinoma by upregulating the Src/Akt/β-catenin pathway and Bcl-2 expression

Oncotarget

Volumn 6, Issue 14, 2015, Pages 12405-12420

  Chen, Junying ^a,b   Yang, Hong ^a,b   Wen, Jing ^a,b   Luo, Kongjia ^a,b   Liu, Qianwen ^a,b   Huang, Yijie ^c   Zheng, Yuzhen ^a,b   Tan, Zihui ^a,b   Huang, Qingyuan ^a,b   Fu, Jianhua ^a,b  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b Guangdong Esophageal Cancer Research Institute   (China)

^c GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Bcl 2; Chemoradiotherapy; Esophageal cancer; NHE9; Src

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; BETA CATENIN; CISPLATIN; DASATINIB; NAVELBINE; NHE9 PROTEIN; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RECEPTOR FOR ACTIVATED C KINASE 1; SODIUM PROTON EXCHANGE PROTEIN; UNCLASSIFIED DRUG; BCL2 PROTEIN, HUMAN; CTNNB1 PROTEIN, HUMAN; SLC9A9 PROTEIN, HUMAN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CANCER STAGING; CHEMORADIOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR VOLUME; UPREGULATION; AGED; ANIMAL; DRUG RESISTANCE; DRUG SCREENING; ESOPHAGUS TUMOR; FLOW CYTOMETRY; GENETIC TRANSFECTION; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; SQUAMOUS CELL CARCINOMA; WESTERN BLOTTING;

AGED; ANIMALS; BETA CATENIN; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; DRUG RESISTANCE, NEOPLASM; ESOPHAGEAL NEOPLASMS; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MALE; MICE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; SODIUM-HYDROGEN ANTIPORTER; SRC-FAMILY KINASES; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84931424800     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3618     Document Type: Article

References (52)

1. Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, Gebski V. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. LANCET ONCOL. 2011; 12:681-692.
2. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge HM, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, Ten KF, Creemers GJ, Punt CJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012; 366:2074-2084.
3. Berger AC, Farma J, Scott WJ, Freedman G, Weiner L, Cheng JD, Wang H, Goldberg M. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J CLIN ONCOL. 2005; 23:4330-4337.
4. Brucher BL, Stein HJ, Zimmermann F, Werner M, Sarbia M, Busch R, Dittler HJ, Molls M, Fink U, Siewert JR. Responders benefit from neoadjuvant radiochemotherapy in esophageal squamous cell carcinoma: results of a prospective phase-II trial. Eur J Surg Oncol. 2004; 30:963-971.
5. Wen J, Yang H, Liu MZ, Luo KJ, Liu H, Hu Y, Zhang X, Lai RC, Lin T, Wang HY, Fu JH. Gene expression analysis of pretreatment biopsies predicts the pathological response of esophageal squamous cell carcinomas to neo-chemoradiotherapy. ANN ONCOL. 2014; 25:1769-1774.
6. Orlowski J, Grinstein S. Diversity of the mammalian sodium/proton exchanger SLC9 gene family. Pflugers Arch. 2004; 447:549-565.
7. Di Sole F, Vadnagara K, Moe OW, Babich V. Calcineurin homologous protein: a multifunctional Ca2+-binding protein family. Am J Physiol Renal Physiol. 2012; 303:F165-F179.
8. Lin X, Barber DL. A calcineurin homologous protein inhibits GTPase-stimulated Na-H exchange. Proc Natl Acad Sci USA. 1996; 93:12631-12636.
9. Onishi I, Lin PJ, Diering GH, Williams WP, Numata M. RACK1 associates with NHE5 in focal adhesions and positively regulates the transporter activity. CELL SIGNAL. 2007; 19:194-203.
10. Ohgaki R, Fukura N, Matsushita M, Mitsui K, Kanazawa H. Cell surface levels of organellar Na+/H+ exchanger isoform 6 are regulated by interaction with RACK1. J BIOL CHEM. 2008; 283:4417-4429.
11. Bertrand B, Wakabayashi S, Ikeda T, Pouyssegur J, Shigekawa M. The Na+/H+ exchanger isoform 1 (NHE1) is a novel member of the calmodulin-binding proteins. Identification and characterization of calmodulin-binding sites. J BIOL CHEM. 1994; 269:13703-13709.
12. Aharonovitz O, Zaun HC, Balla T, York JD, Orlowski J, Grinstein S. Intracellular pH regulation by Na(+)/H(+) exchange requires phosphatidylinositol 4, 5-bisphosphate. J CELL BIOL. 2000; 150:213-224.
13. Franke B, Neale BM, Faraone SV. Genome-wide association studies in ADHD. HUM GENET. 2009; 126:13-50.
14. Kondapalli KC, Hack A, Schushan M, Landau M, Ben-Tal N, Rao R. Functional evaluation of autism-associated mutations in NHE9. NAT COMMUN. 2013; 4:2510.
15. Kim AH, Khursigara G, Sun X, Franke TF, Chao MV. Akt phosphorylates and negatively regulates apoptosis signalregulating kinase 1. MOL CELL BIOL. 2001; 21:893-901.
16. West KA, Castillo SS, Dennis PA. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat. 2002; 5:234-248.
17. Franke TF, Hornik CP, Segev L, Shostak GA, Sugimoto C. PI3K/Akt and apoptosis: size matters. ONCOGENE. 2003; 22:8983-8998.
18. Lu Z, Xu S. ERK1/2 MAP kinases in cell survival and apoptosis. IUBMB LIFE. 2006; 58:621-631.
19. Wada T, Penninger JM. Mitogen-activated protein kinases in apoptosis regulation. ONCOGENE. 2004; 23:2838-2849.
20. Fridman JS, Lowe SW. Control of apoptosis by p53. ONCOGENE. 2003; 22:9030-9040.
21. Haupt S, Berger M, Goldberg Z, Haupt Y. Apoptosis-the p53 network. J CELL SCI. 2003; 116:4077-4085.
22. Burris HR. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. Cancer Chemother Pharmacol. 2013; 71:829-842.
23. Tokunaga E, Kimura Y, Mashino K, Oki E, Kataoka A, Ohno S, Morita M, Kakeji Y, Baba H, Maehara Y. Activation of PI3K/Akt signaling and hormone resistance in breast cancer. BREAST CANCER-TOKYO. 2006; 13:137-144.
24. Kennedy SG, Wagner AJ, Conzen SD, Jordan J, Bellacosa A, Tsichlis PN, Hay N. The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes Dev. 1997; 11:701-713.
25. Mamidipudi V, Cartwright CA. A novel pro-apoptotic function of RACK1: suppression of Src activity in the intrinsic and Akt pathways. ONCOGENE. 2009; 28:4421-4433.
26. Dhanasekaran DN, Reddy EP. JNK signaling in apoptosis. ONCOGENE. 2008; 27:6245-6251.
27. Lopez-Bergami P, Habelhah H, Bhoumik A, Zhang W, Wang LH, Ronai Z. RACK1 mediates activation of JNK by protein kinase C [corrected]. MOL CELL. 2005; 19:309-320.
28. Lin X, Sikkink RA, Rusnak F, Barber DL. Inhibition of calcineurin phosphatase activity by a calcineurin B homologous protein. J BIOL CHEM. 1999; 274:36125-36131.
29. Kiely PA, Sant A, O'Connor R. RACK1 is an insulin-like growth factor 1 (IGF-1) receptor-interacting protein that can regulate IGF-1-mediated Akt activation and protection from cell death. J BIOL CHEM. 2002; 277:22581-22589.
30. Wang HG, Pathan N, Ethell IM, Krajewski S, Yamaguchi Y, Shibasaki F, McKeon F, Bobo T, Franke TF, Reed JC. Ca2+-induced apoptosis through calcineurin dephosphorylation of BAD. SCIENCE. 1999; 284:339-343.
31. Luo H, Yang Y, Huang F, Li F, Jiang Q, Shi K, Xu C. Selenite induces apoptosis in colorectal cancer cells via AKT-mediated inhibition of beta-catenin survival axis. CANCER LETT. 2012; 315:78-85.
32. Pap M, Cooper GM. Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-Kinase/Akt cell survival pathway. J BIOL CHEM. 1998; 273:19929-19932.
33. Pugazhenthi S, Nesterova A, Sable C, Heidenreich KA, Boxer LM, Heasley LE, Reusch JE. Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein. J BIOL CHEM. 2000; 275:10761-10766.
34. Matsuzaki H, Tamatani M, Mitsuda N, Namikawa K, Kiyama H, Miyake S, Tohyama M. Activation of Akt kinase inhibits apoptosis and changes in Bcl-2 and Bax expression induced by nitric oxide in primary hippocampal neurons. J NEUROCHEM. 1999; 73:2037-2046.
35. O'Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, Cowan-Jacob SW, Lee FY, Heinrich MC, Deininger MW, Druker BJ. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. CANCER RES. 2005; 65:4500-4505.
36. Dargart JL, Fish K, Gordon LI, Longnecker R, Cen O. Dasatinib therapy results in decreased B cell proliferation, splenomegaly, and tumor growth in a murine model of lymphoma expressing Myc and Epstein-Barr virus LMP2A. Antiviral Res. 2012; 95:49-56.
37. Tahir SK, Yang X, Anderson MG, Morgan-Lappe SE, Sarthy AV, Chen J, Warner RB, Ng SC, Fesik SW, Elmore SW, Rosenberg SH, Tse C. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. CANCER RES. 2007; 67:1176-1183.
38. Konopleva M, Watt J, Contractor R, Tsao T, Harris D, Estrov Z, Bornmann W, Kantarjian H, Viallet J, Samudio I, Andreeff M. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). CANCER RES. 2008; 68:3413-3420.
39. Liu J, Lin A. Role of JNK activation in apoptosis: a doubleedged sword. CELL RES. 2005; 15:36-42.
40. Adams DR, Ron D, Kiely PA. RACK1, A multifaceted scaffolding protein: Structure and function. CELL COMMUN SIGNAL. 2011; 9:22.
41. Elmore S. Apoptosis: a review of programmed cell death. TOXICOL PATHOL. 2007; 35:495-516.
42. Knuefermann C, Lu Y, Liu B, Jin W, Liang K, Wu L, Schmidt M, Mills GB, Mendelsohn J, Fan Z. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. ONCOGENE. 2003; 22:3205-3212.
43. Banerjee S, Kaye SB. New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential. CLIN CANCER RES. 2013; 19:961-968.
44. Du XL, Yang H, Liu SG, Luo ML, Hao JJ, Zhang Y, Lin DC, Xu X, Cai Y, Zhan QM, Wang MR. Calreticulin promotes cell motility and enhances resistance to anoikis through STAT3-CTTN-Akt pathway in esophageal squamous cell carcinoma. ONCOGENE. 2009; 28:3714-3722.
45. Yoshioka A, Miyata H, Doki Y, Yasuda T, Yamasaki M, Motoori M, Okada K, Matsuyama J, Makari Y, Sohma I, Takiguchi S, Fujiwara Y, Monden M. The activation of Akt during preoperative chemotherapy for esophageal cancer correlates with poor prognosis. ONCOL REP. 2008; 19:1099-1107.
46. Brognard J, Clark AS, Ni Y, Dennis PA. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. CANCER RES. 2001; 61:3986-3997.
47. Kraus AC, Ferber I, Bachmann SO, Specht H, Wimmel A, Gross MW, Schlegel J, Suske G, Schuermann M. In vitro chemo-and radio-resistance in small cell lung cancer correlates with cell adhesion and constitutive activation of AKT and MAP kinase pathways. ONCOGENE. 2002; 21:8683-8695.
48. Chan CM, Jing X, Pike LA, Zhou Q, Lim DJ, Sams SB, Lund GS, Sharma V, Haugen BR, Schweppe RE. Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis. CLIN CANCER RES. 2012; 18:3580-3591.
49. Oakes SR, Vaillant F, Lim E, Lee L, Breslin K, Feleppa F, Deb S, Ritchie ME, Takano E, Ward T, Fox SB, Generali D, Smyth GK, Strasser A, Huang DC, Visvader JE, et al. Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. Proc Natl Acad Sci USA. 2012; 109:2766-2771.
50. Vaillant F, Merino D, Lee L, Breslin K, Pal B, Ritchie ME, Smyth GK, Christie M, Phillipson LJ, Burns CJ, Mann GB, Visvader JE, Lindeman GJ. Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer. CANCER CELL. 2013; 24:120-129.
51. Remmele W, Stegner HE. [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. PATHOLOGE. 1987; 8:138-140.
52. Saussez S, Cucu DR, Decaestecker C, Chevalier D, Kaltner H, Andre S, Wacreniez A, Toubeau G, Camby I, Gabius HJ, Kiss R. Galectin 7 (p53-induced gene 1): a new prognostic predictor of recurrence and survival in stage IV hypopharyngeal cancer. ANN SURG ONCOL. 2006; 13:999-1009.